BioPharmSignal logoBioPharmSignal

Biotech News

Alkermes Announces Launch of 9th Annual Alkermes Pathways Research Awards® Program

Alkermes plc (ALKS)Alkermes plcCommercial

— Competitive Grant Program to Offer Individual Grants of Up to $100,000 per Project — — Areas of Interest Expanded to Include Narcolepsy and Idiopathic Hypersomnia in Addition to Schizophrenia and Bipolar I Disorder — — Stage One Submission Period Runs From Sept. 11, 2026 Through Oct.

Related news

ALKSAlkermes plc2026-06-15 11:00 EST

Alkermes Announces Orphan Drug Designations for Alixorexton in the U.S. and Europe

ALKSAlkermes plc2026-08-24 22:30 EST

The Lancet Neurology Publishes Data From Alkermes’ Positive Vibrance-1 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 1

TNXPTonix Pharmaceuticals2026-09-08 11:00 EST

Tonix Pharmaceuticals Promotes Thomas Englese, MBA, to Chief Commercial Officer

ECORelectroCore2026-08-03 12:00 EST

electroCore to Participate in Upcoming Investor Conferences

NBIXNeurocrine Biosciences2026-07-23 20:05 EST

Neurocrine Biosciences Announces Key Leadership Hiring, Promotions

ECORelectroCore2026-07-16 12:00 EST

New Review Examines Anatomical and Methodological Differences Between Auricular and Cervical Vagus Nerve Stimulation

TNXPTonix Pharmaceuticals2026-08-05 11:00 EST

Tonix Pharmaceuticals to Participate in Upcoming Investor Conferences

ANNXAnnexon, Inc.2026-08-12 10:00 EST

Annexon Expands Vonaprument Phase 3 Program in Geographic Atrophy with Addition of Month 24 Dual Primary Endpoint Complementing Month 15 Primary Endpoint and Launch of Open-Label Extension Study

XENEXenon2026-09-17 20:01 EST

Xenon Announces Azetukalner NDA Submission to FDA for Focal Seizures and Provides Update on Psychiatry Clinical Program

View all latest news

Alkermes plc

Alkermes is a biopharmaceutical company focused on neuroscience, addiction medicine, and specialty therapeutics. Its portfolio combines commercial products and development programs across CNS and related areas.

Recent company news

ALKSAlkermes plc2026-09-16 11:00 EST

Alkermes Announces Appointment of Anne C. Whitaker to Board of Directors

ALKSAlkermes plc2026-09-10 11:00 EST

Alkermes Announces Launch of 9th Annual Alkermes Pathways Research Awards® Program

ALKSAlkermes plc2026-08-24 22:30 EST

The Lancet Neurology Publishes Data From Alkermes’ Positive Vibrance-1 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 1

ALKSAlkermes plc2026-07-28 11:00 EST

Alkermes plc Reports Second Quarter 2026 Financial Results

ALKSAlkermes plc2026-07-14 20:00 EST

Alkermes to Report Second Quarter Financial Results on July 28, 2026

Stock data

Close
46.71 USD
Market cap
6.89B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States